Background on Acute Myeloid Leukemia

Acute Myeloid Leukemia stands as a formidable adversary in the landscape of hematological oncology. Characterized by the rapid proliferation of abnormal myeloid cells that crowd out healthy blood cells in the bone marrow, AML presents a complex therapeutic challenge that has perplexed clinicians for decades1. The disease's aggressive nature demands prompt intervention, yet the very treatments designed to combat it often impose their own substantial burdens upon patients already weakened by malignancy.

The pathophysiology of AML involves a series of genetic mutations that disrupt normal hematopoietic differentiation, leading to the accumulation of immature blast cells 2. These malignant cells proliferate uncontrollably, suppressing the production of functional erythrocytes, leukocytes, and platelets. The clinical consequences manifest as anemia, increased susceptibility to infections, and bleeding tendencies, all of which significantly compromise patient quality of life and survival prospects.

Globally, AML accounts for approximately 80% of acute leukemia cases in adults, with incidence rates increasing markedly with age 3. The prognosis remains guarded, with five-year survival rates hovering around 25-30% in most populations 4. However, these statistics mask considerable heterogeneity based on cytogenetic risk stratification, molecular mutations, patient age, and performance status at diagnosis 5.

The Challenge of Traditional Chemotherapy

For over four decades, the backbone of AML induction therapy has remained the so-called "3+7" regimen, consisting of three days of anthracycline administration (typically daunorubicin) combined with seven days of continuous cytarabine infusion 6. This approach, while capable of inducing remission in a subset of patients, exacts a considerable toll in terms of treatment-related toxicity 7.

The cytotoxic nature of traditional chemotherapy indiscriminately targets all rapidly dividing cells, including healthy hematopoietic progenitors, gastrointestinal epithelium, and hair follicles 8. The resulting pancytopenia leaves patients vulnerable to life-threatening infections and hemorrhagic complications, necessitating prolonged hospitalization, intensive supportive care, and frequent blood product transfusions 9. Historical studies demonstrate that even in well-controlled trials of selected older patients, early mortality rates of 10-25% occur with intensive chemotherapy ¹⁰.

Treatment Protocols

In the context of Pakistan's healthcare system, these challenges assume even greater significance. Limited access to specialized hematology services, blood bank resources, and antimicrobial therapies can transform manageable complications into life-threatening crises. Furthermore, the economic burden of prolonged hospitalization and supportive care places immense strain on families, often forcing difficult decisions about treatment continuation.

Against this backdrop, the emergence of targeted therapeutic agents has generated considerable interest among hematologists worldwide. Venetoclax, a selective inhibitor of the BCL-2 protein, represents a paradigm shift in AML treatment, offering the promise of effective leukemia control with reduced collateral damage to normal tissues 11. The VIALE-A and VIALE-C phase 3 trials established venetoclax combinations as new standards of care for elderly or unfit patients with AML¹²,¹³.

Study Design and Patient Selection This prospective comparative study was conducted at Ayub Teaching Hospital, a tertiary care facility serving the Abbottabad region of Khyber Pakhtunkhwa province in Pakistan. The investigation enrolled thirty patients newly diagnosed with Acute Myeloid Leukemia between January and October 2024, with follow-up continuing through the study period. Patient eligibility criteria included confirmed diagnosis of AML based on bone marrow examination and immunophenotyping, age between 10 and 70 years, and provision of informed consent for treatment. Patients with acute promyelocytic leukemia, prior chemotherapy exposure, or severe comorbidities precluding either treatment approach were excluded from participation. Participants were allocated to treatment groups based on clinical judgment, patient preference, and resource availability. Group A comprised ten patients who received the traditional 3+7 regimen, while Group B consisted of twenty patients treated with the venetoclax-based protocol. Baseline demographic and clinical characteristics were comparable between groups, though the venetoclax cohort included a higher proportion of elderly patients deemed unsuitable for intensive chemotherapy. Group A: Traditional 3+7 Regimen Patients assigned to the conventional treatment arm received daunorubicin at a dose of 60 mg per square meter of body surface area daily for three consecutive days, administered intravenously. This was combined with cytarabine 100 mg per square meter daily as a continuous intravenous infusion over seven days. The regimen followed established protocols with appropriate hydration, antiemetic prophylaxis, and tumor lysis syndrome precautions. Group B: Cytosar Plus Venetoclax The investigational arm employed a modified protocol combining low-dose cytarabine with venetoclax. Cytarabine was administered subcutaneously at a dose of 40 mg daily for seven days each month. Venetoclax was given orally at a dose of 400 mg daily, with dose escalation following the standard ramp-up schedule to minimize tumor lysis syndrome risk. This regimen was continued for induction and consolidation phases as clinically indicated. Both groups received standard supportive care including antimicrobial prophylaxis, transfusion support as needed, and growth factor administration per institutional protocols. Response assessment was performed through serial bone marrow examinations, complete blood counts, and clinical evaluation.

The comparative analysis revealed striking differences in clinical outcomes between the two treatment cohorts, with the venetoclax-based regimen demonstrating superior efficacy and markedly improved safety profile across all measured parameters.

Survival Outcomes

The most dramatic divergence between treatment groups was observed in survival outcomes. Among the ten patients receiving the traditional 3+7 regimen, only two individuals (20%) survived to the end of the study period. The remaining eight patients succumbed to treatment-related complications, primarily severe infections and hemorrhagic events arising from profound cytopenia.

In stark contrast, the venetoclax cohort achieved a survival rate of 90%, with eighteen of twenty patients remaining alive at study completion. This four-and-a-half-fold improvement in survival represents a clinically meaningful advance that could transform the therapeutic landscape for AML in our setting.

Toxicity and Side Effect Profile

The safety analysis demonstrated substantial differences in treatment tolerability between the two regimens. Severe cytopenia, defined as grade 3 or 4 neutropenia, thrombocytopenia, or anemia requiring intervention, occurred in 80% of patients receiving the 3+7 regimen compared to only 15% of those on the venetoclax-based approach.

Transfusion dependency showed an even more pronounced disparity. Ninety percent of patients in the traditional chemotherapy group required repeated blood product transfusions throughout their treatment course, placing significant demand on blood bank resources and exposing patients to transfusion-related risks. In the venetoclax arm, only 15% of patients required transfusion support, with most maintaining adequate blood counts throughout therapy.

Hospital utilization metrics further illustrated the differential burden of the two approaches. Patients receiving the 3+7 regimen averaged twelve hospital visits per individual, encompassing admission for chemotherapy administration, management of neutropenic fever, transfusion support, and treatment of infectious complications. The venetoclax cohort averaged merely four hospital visits per patient, reflecting the outpatient-friendly nature of this regimen

Quality of Life Assessment

Beyond objective clinical endpoints, patient-reported quality of life metrics revealed meaningful differences between treatment experiences. Patients receiving the 3+7 regimen consistently described feeling "constantly sick," with prolonged hospitalizations, recurrent febrile episodes, and profound fatigue dominating their treatment course. Many expressed frustration at the disconnect between treatment intent and the reality of their experience.

Conversely, patients on the venetoclax regimen frequently reported feeling "almost normal" throughout much of their treatment. The ability to receive therapy in an outpatient setting, maintain employment or household responsibilities, and avoid the cycle of infectious complications contributed to a substantially different treatment experience.

Table 1: Comparative outcomes between treatment groups

Comparison with International Literature

The findings of our investigation align closely with emerging international evidence supporting the efficacy of venetoclax-based regimens in AML management. The VIALE-A trial, published in the New England Journal of Medicine in 2020, demonstrated that patients receiving venetoclax in combination with azacitidine achieved 34% reduction in risk of death compared to azacitidine alone, with median overall survival of 14.7 versus 9.6 months¹². Our observed survival advantage, while even more pronounced, is consistent with this established benefit. The VIALE-C trial 13, published in the New England Journal of Medicine in 2020, demonstrated that patients receiving venetoclax in combination with low-dose cytarabine achieved approximately 50% longer overall survival compared to those receiving cytarabine alone. Our observed survival advantage, while even more pronounced, is consistent with this established benefit.

Similarly, a Japanese study 14 published in 2023 reported a 55% remission rate among AML patients treated with venetoclax-based therapy, with participants requiring fewer hospitalizations and experiencing generally mild side effects. These observations mirror our own experience and suggest that the benefits of this approach may be generalizable across diverse patient populations.

Real-world evidence from the United Kingdom NHS demonstrated that venetoclax-azacitidine achieved CR/CRi rates of 67% with median overall survival of 13.6 months in a cohort of 587 patients, remarkably consistent with clinical trial outcomes 15. These observations mirror our own experience and suggest that the benefits of this approach may be generalizable across diverse patient populations and healthcare settings.

A systematic review and meta-analysis of venetoclax combinations confirmed superior overall efficacy compared to hypomethylating agent monotherapy, with higher complete remission rates and acceptable safety profiles16. Notably, real-world studies demonstrate that while healthcare resource utilization remains substantial during the first treatment cycle, supportive care requirements significantly decrease thereafter, contrasting with the continuous high resource demands of intensive chemotherapy17

Mechanism of Action

The superior efficacy and safety profile of venetoclax can be understood through its unique mechanism of action. Unlike traditional cytotoxic chemotherapy, which indiscriminately attacks all rapidly dividing cells, venetoclax represents a precision therapeutic approach targeting a specific molecular vulnerability in leukemia cells ¹⁸.

BCL-2 is an anti-apoptotic protein that plays a critical role in cell survival by preventing programmed cell death. In many AML cases, leukemia cells become dependent on BCL-2 for their continued survival, making this protein an attractive therapeutic target ¹⁹. Venetoclax functions as a selective BCL-2 inhibitor, binding to the protein and displacing pro-apoptotic mediators that subsequently trigger cell death pathways ¹⁸.

This targeted mechanism explains both the efficacy and favorable toxicity profile observed in our study. By specifically targeting leukemia cells while sparing normal hematopoietic progenitors to a greater extent than conventional chemotherapy, venetoclax achieves disease control with reduced myelosuppression and its attendant complications ¹⁹.

Clinical Implications

The results of this study carry significant implications for clinical practice, particularly in resource-constrained settings such as Pakistan. The reduced need for blood product transfusions, decreased hospitalization requirements, and lower incidence of infectious complications translate into tangible benefits for both patients and healthcare systems.

For patients, the ability to receive effective cancer therapy while maintaining a reasonable quality of life represents a meaningful advance. The outpatient administration schedule reduces disruption to family life, employment, and social functioning. The lower incidence of severe side effects decreases the psychological burden of treatment and may improve adherence to prescribed therapy.

From a healthcare system perspective, the reduced resource utilization associated with venetoclax-based therapy offers potential cost savings despite the higher acquisition cost of the targeted agent. Fewer hospital admissions, reduced transfusion requirements, and decreased antimicrobial utilization may offset drug costs while simultaneously improving patient outcomes.

Particularly noteworthy is the suitability of this regimen for elderly patients and those with comorbidities who would traditionally be considered ineligible for intensive chemotherapy. Our findings suggest that venetoclax-based therapy may extend effective treatment options to a broader patient population, addressing an important unmet need in AML management.

Limitations

Several limitations of this study should be acknowledged when interpreting the findings. The most significant constraint is the relatively small sample size, with only thirty patients enrolled across both treatment arms. This limited number reduces statistical power and may affect the generalizability of our observations to broader patient populations.

The non-randomized design introduces the possibility of selection bias, as treatment assignment was influenced by clinical judgment and patient factors rather than random allocation. Patients assigned to the venetoclax arm may have differed in unmeasured ways from those receiving traditional chemotherapy, potentially confounding the observed outcomes.

The single-center nature of the study limits geographic generalizability, as patient characteristics, supportive care practices, and infectious disease epidemiology may differ across institutions and regions. Furthermore, the relatively short follow-up period precludes assessment of long-term outcomes such as disease-free survival and late treatment effects.

Despite these limitations, the magnitude of the observed differences between treatment groups, combined with consistency with international literature, supports the validity of our conclusions. Nevertheless, larger, multicenter, randomized controlled trials conducted within South Asian populations would strengthen the evidence base and provide more definitive guidance for clinical practice.

This comparative study provides compelling evidence that venetoclax combined with low-dose cytarabine offers a safer and more effective therapeutic approach for Acute Myeloid Leukemia compared to the traditional 3+7 regimen in our clinical setting. The four-fold improvement in survival, dramatic reduction in treatment-related toxicity, and enhanced quality of life collectively represent a meaningful advance in AML management.

The findings are particularly relevant for healthcare systems facing resource constraints, where the reduced transfusion requirements, decreased hospitalization needs, and lower infectious complication rates associated with venetoclax-based therapy translate into tangible benefits for both patients and healthcare providers.

As experience with venetoclax-based regimens accumulates globally, our study contributes important real-world evidence from a South Asian population that complements data from controlled clinical trials. We believe these findings support the consideration of venetoclax-based therapy as a preferred treatment option for appropriate AML patients, particularly those who are elderly or possess comorbidities that would preclude intensive chemotherapy.

Future research should focus on optimizing patient selection, refining dosing protocols, and establishing long-term outcomes in our population. The integration of molecular profiling to identify patients most likely to benefit from BCL-2 inhibition represents a promising avenue for personalized AML therapy

1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593-606.
2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
4. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
5. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
6. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896-903.
7. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m² vs 60 mg/m² in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878-3885.
8. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
9. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients with acute myeloid leukemia. Blood. 2010;116(22):4422-4429.
10. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187.
11. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
12. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
13. Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137-2145.
14. Morita Y, Kanazawa H, Fujiwara Y, et al. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan. Int J Hematol. 2023;118(1):96-105.
15. Othman J, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024.
16. Amador-Medina LF, et al. Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review. Hematol Transfus Cell Ther. 2024;46(4):421-428.
17. Al-Kali A, et al. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. Cancer Med. 2022;11(9):1919-1931.
18. Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120-1136.
19. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106-1117